Characterization of SARS-CoV-2 Escape Mutants to a Pair of Neutralizing Antibodies Targeting the RBD and the NTD
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: International Journal of Molecular Sciences 23.15 (2022): 8177.
- Ereignis
-
Veröffentlichung
- (wo)
-
Erlangen
- (wer)
-
Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
- (wann)
-
2022
- Urheber
-
Peter, Antonia Sophia
Grüner, Eva
Socher, Eileen
Fraedrich, Kirsten
Richel, Elie
Mueller-Schmucker, Sandra
Cordsmeier, Arne
Ensser, Armin
Sticht, Heinrich
Überla, Klaus
- DOI
-
10.3390/ijms23158177
- URN
-
urn:nbn:de:bvb:29-opus4-206119
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:54 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Peter, Antonia Sophia
- Grüner, Eva
- Socher, Eileen
- Fraedrich, Kirsten
- Richel, Elie
- Mueller-Schmucker, Sandra
- Cordsmeier, Arne
- Ensser, Armin
- Sticht, Heinrich
- Überla, Klaus
- Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
Entstanden
- 2022
Ähnliche Objekte (12)
Quantitation of SARS-CoV-2 neutralizing antibodies using virus-like particles
Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus
Neutralizing antibodies as tools for structure-based vaccine design
A pair of noncompeting neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model
Utility of different surrogate enzyme-linked immunosorbent assays (sELISAs) for detection of SARS-CoV-2 neutralizing antibodies
Identification and characterization of broadly neutralizing antibodies targeting viral infections
Development of neutralizing and non-neutralizing antibodies targeting known and novel epitopes on Clostridioides difficile Toxin B
Kinetics of Nucleo- and Spike Protein-Specific Immunoglobulin G and of Virus-Neutralizing Antibodies after SARS-CoV-2 Infection
Peptide variants of a SARS-CoV-2 neutralizing protein
Development of SARS-CoV-2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of Concern or Vaccination
tANCHOR-cell-based assay for monitoring of SARS-CoV-2 neutralizing antibodies rapidly adaptive to various receptor-binding domains
Pharmacokinetics and Immunogenicity of Broadly Neutralizing HIV Monoclonal Antibodies in Macaques
Quantitation of SARS-CoV-2 neutralizing antibodies using virus-like particles
Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus
Neutralizing antibodies as tools for structure-based vaccine design
A pair of noncompeting neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model
Utility of different surrogate enzyme-linked immunosorbent assays (sELISAs) for detection of SARS-CoV-2 neutralizing antibodies
Identification and characterization of broadly neutralizing antibodies targeting viral infections
Development of neutralizing and non-neutralizing antibodies targeting known and novel epitopes on Clostridioides difficile Toxin B
Kinetics of Nucleo- and Spike Protein-Specific Immunoglobulin G and of Virus-Neutralizing Antibodies after SARS-CoV-2 Infection
Peptide variants of a SARS-CoV-2 neutralizing protein
Development of SARS-CoV-2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of Concern or Vaccination
tANCHOR-cell-based assay for monitoring of SARS-CoV-2 neutralizing antibodies rapidly adaptive to various receptor-binding domains
Pharmacokinetics and Immunogenicity of Broadly Neutralizing HIV Monoclonal Antibodies in Macaques
Quantitation of SARS-CoV-2 neutralizing antibodies using virus-like particles
Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus
Neutralizing antibodies as tools for structure-based vaccine design
A pair of noncompeting neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model
Utility of different surrogate enzyme-linked immunosorbent assays (sELISAs) for detection of SARS-CoV-2 neutralizing antibodies
Identification and characterization of broadly neutralizing antibodies targeting viral infections
Development of neutralizing and non-neutralizing antibodies targeting known and novel epitopes on Clostridioides difficile Toxin B
Kinetics of Nucleo- and Spike Protein-Specific Immunoglobulin G and of Virus-Neutralizing Antibodies after SARS-CoV-2 Infection
Peptide variants of a SARS-CoV-2 neutralizing protein
Development of SARS-CoV-2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of Concern or Vaccination
tANCHOR-cell-based assay for monitoring of SARS-CoV-2 neutralizing antibodies rapidly adaptive to various receptor-binding domains